SCHEMBL712431

SCHEMBL712431

CC(C)(C)n1nc(Cc2ccc(Cl)cc2)cc1Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 6/20 0.66
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PPIA P62937 1/20 0.50
KMT2A Q03164 3/20 0.49
SCN3A Q9NY46 2/20 0.49
MEN1 O00255 2/20 0.49
SCN5A Q14524 1/20 0.49
ALOX12 P18054 1/20 0.47
CCNT1 O60563 1/20 0.47
CDK9 P50750 1/20 0.47
AVPR2 P30518 1/20 0.46
GPR27 Q9NS67 1/20 0.46
ALDH1A1 P00352 1/20 0.44
EGFR P00533 1/20 0.44
KDR P35968 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712664 0.91 SCN9A (0.55) SCN9ALMNASMN1; SMN2PPIAKMT2A
SCHEMBL712892 0.89 SCN9A (0.63) SCN9ALMNASMN1; SMN2PPIAKMT2A
SCHEMBL710233 0.88 SCN9A (0.62) SCN9ASCN3ASCN5A
SCHEMBL711567 0.86 SCN9A (0.49) SCN9AKMT2AMEN1
SCHEMBL712534 0.85 SCN9A (0.54) SCN9ALMNASMN1; SMN2PPIAKMT2A
SCHEMBL713144 0.84 SCN9A (0.53) SCN9ALMNASMN1; SMN2PPIAKMT2A
SCHEMBL713267 0.83 KDM4E (0.53) SCN9ALMNASMN1; SMN2KMT2AMEN1
SCHEMBL713743 0.81 KMT2A (0.52) SCN9ALMNASMN1; SMN2PPIAKMT2A
SCHEMBL711214 0.81 SCN9A (0.53) SCN9APPIAKMT2ASCN3AMEN1
SCHEMBL711822 0.80 SCN9A (0.53) SCN9ASCN3ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2178873-A1 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS N.V. Organon (NL) 2010-04-28 EP disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009010491-A1 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS N.V. ORGANON (NL) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN9A 17/4885LMNA 2921/4885SMN1; SMN2 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.